Some studies demonstrated that, in melanoma tumors and TNBC, the WNT signalling can control the expression of PD-L1 and CTLA-4, as well as have the capacity to regulate the tumor-immune cycle in all steps [92,93,94]. This evidence concerns the gene CTLA4 and melanoma.